
Background
Using synthetic biology methods, the Escherichia coli K-12 genome was reduced by making a series of planned, precise deletions. The multiple-deletion series (MDS™) strains (1), with genome reduction of up to 15%, were designed by identifying non-essential genes and sequences for elimination, including recombinogenic or mobile DNA and cryptic virulence genes, while preserving robust growth and protein production. Genome reduction also led to unanticipated beneficial properties, including high electroporation efficiency and accurate propagation of recombinant genes and plasmids that are unstable in other strains. Subsequent deletions and introduction of useful alleles produce strains suitable for many molecular biology applications. Recently, Scarab has built on the MDS™42 foundation strain, by creating the MDS™42 Meta ΔrecA strain. It improves the already high density fermentation of the MDS™42 strain. The MDS™42 Meta ΔrecA strain’s optimized metabolism permits fermentation ≥OD300 in minimal media in ~24 hrs without glucose spike or cell lysis resulting in >40 g/L of a test protein at the 10 liter scale. It produced ~700 mg/L of pGWIZ GFP test plasmid in minimal media at the 10 liter scale without a temperature shift.
Figures
Figure 1. High Plasmid Yield without a Temperature Shift using Minimal Media. The MDS™42 Meta ΔrecA strain produced ~700 mg/L of pGWIZ GFP test plasmid in 10 liter scale fed batch fermentation without a temperature shift using Scarab’s ultra minimal media.
Figure 2: Multiple Deletion Strains tolerate "deleterious” genes. A chimeric gene composed of VP60 of rabbit hemorrhagic disease virus fused to the B subunit of cholera toxin (CTX) was very unstable in E. coli. Individually, both genes were stable in E. coli HB101, C600 and DH10B, but pCTXVP60 carrying the fusion gene in the same hosts did not produce fusion protein and was recovered in low yields. All recovered plasmids contained mutations in the CTXVP60 open reading frame, virtually all resulting from IS insertions. In contrast, the recombinant plasmid was completely stable in MDS™; normal yields of plasmid DNA were obtained. Representative restriction patterns of pCTXVP60. (A) Plasmid DNA from MDS™42 was transformed and propagated in the indicated host, then digested with NcoI and EcoRI. A representative of each restriction pattern was purified and sequenced. M, molecular weight marker, 1 kbp ladder; 1, MDS™41, no insertion; 2, MDS™42, no insertion; 3, DH10B, IS10 insertion; 4, DH10B, IS10 insertion/deletion; 5, C600, IS5 insertion; 6, C600, IS1 insertion; 7, C600, IS1 insertion. (B) Relative position of the IS element insertion sites in the CTXVP60 reading frame determined for the five examples presented.
Figure 3: Plasmid stability in different host strains. Left: during four subcultures of pT-ITR, a plasmid with viral LTR segments; Lane 0, isolated plasmid DNA before subculture, lanes 1-4, successive subcultures. Plasmid DNA was digested with restriction enzymes and analyzed by agarose gel electrophoresis. KpnI cuts the plasmid at a single site, but in MG1655 two bands indicate a deletion in the plasmid. MscI cuts at two locations, but in MG1655 a third intermediate band confirms that the plasmid is deleted. Right: Stability of four variants of a Lentiviral expression plasmid in MDS™42 ΔrecA and Stbl3™ (Life Technologies), showing the proportion of transformants containing intact plasmids (Table 2 BioTechniques 43:466-470 (October 2007)(2).
Specifications
Kit Components MDS™42 Meta ΔrecA Chemically Competent Cells pUC19 Control DNA (10 pg/µl) SOC Medium Genotypes MG1655 multiple-deletion strain (1) relA* Δrph ΔarpA ΔiclR ilvG+ ΔrecA(1819). Quality Control Transformation efficiency is tested using pUC19 control DNA, performed in duplicate. Transformed cells are plated on LB plates containing 50 μg/ml carbenicillin. Transformation efficiency is ≥1x108 cfu/μg DNA.
Storage Conditions Store components at –80°C. Do not store cells in liquid nitrogen.
Related Products
White Glove IS Detection Kit
Support
Product Manuals MDS™42 Meta ΔrecA Chemically Competent Cell Kit Papers
- Pósfai G, et al., (2006) Emergent properties of reduced-genome Escherichia coli. Science 312:1044-6.
- Chacko S. Chakiath, CS & Esposito, D (2007): Improved recombinational stability of lentiviral expression vectors using reduced-genome Escherichia coli. BioTechniques 43:466-470.
Patents & Disclaimers
Products are sold for non-commercial use only, under Scarab Genomics limited use label license: Limited Label Use.Scarab is providing you with this Material subject to the non-transferable right to use the subject amount of the Material for your research at your academic institution. The Recipient agrees not to sell or otherwise transfer this Material, or anything derived or produced from the Material to a third party. NO RIGHTS ARE PROVIDED TO USE THE MATERIAL OR ANYTHING DERIVED OR PRODUCED FROM THE MATERIAL FOR COMMERCIAL PURPOSES. If the Recipient makes any changes to the chromosome of the Material that results in an invention in breach of this limited license, then Scarab will have a worldwide, exclusive, royalty-free license to such invention whether patentable or not. If the Recipient is not willing to accept the terms of this limited license, Scarab is willing to accept return of this product with a full refund, minus shipping and handling costs. For information on obtaining a license to this Material for purposes other than research, please contact Scarab’s Licensing Department. Scarab Genomics’ technology is covered by U.S. Pat. No. 6,989,265 and related foreign applications. Clean Genome® is a registered trademark of Scarab Genomics, LLC.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
关于一般所说的血清,在这大约要先分清楚什么叫血清,什么叫单抗治疗剂(在大陆医院及一般人也叫血清)
血清,如果正常而言是从病患犬只身上抽取血液而提炼制成的一种抗体,例如从一只患有犬瘟的患犬经过长期治疗痊愈后,将他的血液抽取出来,经过粹取提炼,而这种提炼出来的血清(免疫抗体),是有治疗加预防犬瘟的效果,同样包括其它另5种致命性病毒如细小肠炎,犬勾螺旋病毒,犬肝炎,犬黄胆等也同样是这样提炼,但是患犬经过治疗痊愈性低而且提炼血清需要大量的血液才能提炼(例如500ml的血液才经过筛检提炼为2.8ml的血清,而一只患犬需要注射治疗预防是需要2.5mlX5剂,试问这种高消耗经济成本时间的脆取提炼法,谁愿意去做)
因此早期国外会将犬只的各种致命性病毒,注射入牛,马,羊,猪等足蹄类动物身体内,再藉由这些动物的血液来脆取提炼犬病毒血清(这些病毒会在这些足蹄类动物身上起一些作用,但却不会致命!而这些动物的血液也够多够充沛来做提炼),经过多年试验中以羊只的血液提炼血清是比较有效果的!
而目前大陆中也是采用相同的方式提炼血清,但是实验对象包括牛马猪羊等足蹄动物,而再粹取血清的过程除了提炼过程严谨也要有相当的保存过程,这两者只要有一个环节有不当,提炼出的血清就会产生极大的不稳定性甚至于无效!!!
这也就是我们常说血清的由来,因为粹取对像非犬只类,加上或许运送或保存或粹取过程(这都是我们无法见到及预期的可変因素)因此血清的作用几乎就大打折扣了,一般使用血清是用于幼中期犬集体长途运输,或是对于一些大犬只因某些原因不能注射疫苗而又需要加强自身免疫时就需要注射(血清是属于一种短暂时提升免疫体的做法),而真正正本清源,是等小狗或大狗身体健康时,注射2-3剂疫苗来确定自身免疫预防!!
也就是说,很多医生或宠物店会因为不完全了解小狗自身情况如何之前,会给狗狗注射血清,希望提高狗狗的免疫抗体,而等狗狗身体和情绪稳定,再开始接种疫苗,但是,前文中也提过,有太多不可预期性会发生,如小狗太早断奶或母乳不足,血清自身因保存或运输不当!这些太多不确定因素造成血清无效外,更容易害了犬只!!
过来我们谈单抗治疗剂,这种疗剂我们称为单抗疫苗(根据犬只患病不同而施以不同的单病毒对抗疗剂,例如犬瘟单抗,细小单抗),这是属于人工合成的活化菌体,其实也很像疫苗指是因为合成为比疫苗更微弱毒性,它是需要一连施打4-5剂,才有作用的针剂,它的作用我大约解释一下,这种抗体是经过人工更弱化的病毒,而注入患犬体内是激发狗狗自身免疫力对这种病毒进行适应力而加以消灭,因此需要施打五剂,等狗狗自身免疫被激发对这种病毒产生抵抗力(排斥性),
狗自生免疫系统就会针对侵入的单种病毒进行围剿消灭,而等自身免疫力能消灭侵入病毒后,狗的身体内这单种病毒病也就会痊愈(当然这只是针对单一种病毒而言,而患病犬只通常并发并非单一种病症,因此要确实诊断使用支持对症诊疗法举个例,如犬瘟并发呼吸道葡萄球链菌引发流鼻涕咳嗽症状,既使犬瘟病毒被消灭但是葡萄球链菌并不会因犬瘟病毒被消灭而停止作怪,医生还是要针对葡萄链球菌作抗生素注射治疗),而痊愈后的狗,自生免疫力会对单一病毒产生终生排斥作用,例如犬只经过细小治愈后,这只狗终身对细小病毒免疫,既使给狗只注射六联疫苗,疫苗内的弱化细小病毒一样被狗狗自身免疫力排斥消灭,而其它五种疫苗却会再犬只身上起作用(既使得犬瘟医治好的狗能终生预防犬瘟,也同样要打疫苗,因为致命性病毒不是只有犬瘟一种,除非你加狗狗天生利害能六种病都得到而又都医治好!这种可能性太低也千万保佑别这么做狗狗和饲主都太辛苦)!
这也就是为什么患病犬只到医院被确诊为细小或犬瘟时,医生又要打血清的原因(其实是单抗),当然单抗不是万灵丹,它只是加强犬只自身激发免疫的一种催化剂,若是犬只本身体质虚弱或是病毒已经大面积侵犯犬只器官,这些治疗方式都只是一种尽人事听天命的方法了!!!
纤维蛋白已被除去(如通过血凝或去纤维蛋白法)的血浆
血液凝固析出的淡黄色透明液体。如将血液自血管内抽出,放入试管中,不加抗凝剂,则凝血反应被激活,血液迅速凝固,形成胶冻。凝血块收缩,其周围所析出之淡黄色透明液体即为血清,也可于凝血后经离心取得。在凝血过程中,纤维蛋白原转变成纤维蛋白块,所以血清中无纤维蛋白原,这一点是与血浆最大的区别。而在凝血反应中,血小板释放出许多物质,各凝血因子也都发生了变化。这些成分都留在血清中并继续发生变化,如凝血酶原变成凝血酶,并随血清存放时间逐渐减少以至消失。这些也都是与血浆区别之处。但大量未参加凝血反应的物质则与血浆基本相同。为避免抗凝剂的干扰,血液中许多化学成分的分析,都以血清为样品。(右图为血清蛋白)
作用:
●提供基本营养物质:氨基酸、维生素、无机物、脂类物质、核酸衍生物等,是细胞生长必须的物质。
●提供激素和各种生长因子:胰岛素、肾上腺皮质激素(氢化可的松、地塞米松)、类固醇激素(雌二醇、睾酮、孕酮)等。生长因子如成纤维细胞生长因子、表皮生长因子、血小板生长因子等。
●提供结合蛋白:结合蛋白作用是携带重要地低分子量物质,如白蛋白携带维生素、脂肪、以及激素等,转铁蛋白携带铁。结合蛋白在细胞代谢过程中起重要作用。
●提供促接触和伸展因子使细胞贴壁免受机械损伤。
●对培养中的细胞起到某些保护作用:有一些细胞,如内皮细胞、骨髓样细胞可以释放蛋白酶,血清中含有抗蛋白酶成分,起到中和作用。这种作用是偶然发现的,现在则有目的的使用血清来终止胰蛋白酶的消化作用。因为胰蛋白酶已经被广泛用于贴壁细胞的消化传代。血清蛋白形成了血清的粘度,可以保护细胞免受机械损伤,特别是在悬浮培养搅拌时,粘度起到重要作用。血清还含有一些微量元素和离子,他们在代谢解毒中起重要作用,如SeO3,硒等。
本人做动物实验,每组设7只,需要测定小鼠的相关指标,初次接触有几点不明白
1、测定指标时,是否可以每组7只,每只测定一次,一共测定7次?
2、是否可以每组选择3只,每只测定一次,共3次?
3、是否可以每组选择3只,每只自身平行测定3次,共9次?
4、测定指标时,是否可以前3只鼠测定A指标,后4只鼠测定B指标吗?
请问1、2、3中的三个方法哪种方法是否具有可行性?4中的测定方法是否可以?
1)提供基本营养物质:氨基酸、维生素、无机物、脂类物质、核酸衍生物等,是细胞生长必须的物质。
2)提供结合蛋白:结合蛋白作用是携带重要地低分子量物质,如白蛋白携带维生素、脂肪、以及激素等,转铁蛋白携带铁。结合蛋白在细胞代谢过程中起重要作用。
3)提供激素和各种生长因子:胰岛素、肾上腺皮质激素(氢化可的松、地塞米松)、类固醇激素(雌二醇、睾酮、孕酮)等。生长因子如成纤维细胞生长因子、表皮生长因子、血小板生长因子等。
4)对培养中的细胞起到某些保护作用:有一些细胞,如内皮细胞、骨髓样细胞可以释放蛋白酶,血清中含有抗蛋白酶成分,起到中和作用。这种作用是偶然发现的,现在则有目的的使用血清来终止胰蛋白酶的消化作用。因为胰蛋白酶已经被广泛用于贴壁细胞的消化传代。血清蛋白形成了血清的粘度,可以保护细胞免受机械损伤,特别是在悬浮培养搅拌时,粘度起到重要作用。血清还含有一些微量元素和离子,他们在代谢解毒中起重要作用,如SeO3,硒等
5)提供促接触和伸展因子使细胞贴壁免受机械损伤。
6)血清中有抗体,这是被称作免疫球蛋白的蛋白质,血清可以抗病毒,增强抵抗力血清属于生物制剂。
想做临床的血标本的一些代谢组学研究,不知道应该用血浆还是血清,大家的说法好像也不太一致,请大神指导啊,最好有些参考文献,谢谢!

